Results from a US retrospective study suggest that usage rates of SGLT2 inhibitors remain low in people with type 2 diabetes, particularly among Black and Asian individuals, women, and lower-income groups.
Women naturally have lower levels of hepatic and pancreatic fat than men, but having type 2 diabetes removes this advantage and confers a relatively larger increase in cardiovascular risk, show further data from DiRECT.
People with type 1 diabetes who are “hyperglycemia aversive” reduce their hyperglycemia exposure at the cost of increased hypoglycemia and, potentially, reduced hypoglycemia awareness, research suggests.
COVID-19 restrictions do not significantly impact glycated hemoglobin levels in individuals with type 2 diabetes, but those with poor psychologic wellbeing may experience worsening glycemic control, suggest findings from an Italian study.
Findings from a US randomized controlled trial suggest that add-on treatment with the SGLT2 inhibitor dapagliflozin reduces levels of some vasoconstrictors and increases some vasodilators in people with type 2 diabetes.
Flash glucose monitoring is associated with small but sustained improvements in glycemic control and a reduction in severe hypoglycemia relative to self-monitoring of blood glucose in type 1 diabetes, observational data show.